NAKA - NASDAQ
Nakamoto Inc.
$4.96
+0.58%Kindly MD, Inc., a healthcare and healthcare data company, provides direct health care services to patients integrating prescription medicine and behavioral health services. The company offers specialty outpatient clinical services based on a subscription and fee-for-service basis to augment traditional healthcare. It provides evaluation and management services, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support, overdose education, peer support, limited urgent care, preventative medicine, travel, and hormone therapy; and data collection and research, and online and email campaign marketing services, as well as engages in the retail sale of health care products through clinics and online. Kindly MD, Inc. was formerly known as Utah Therapeutic Health Center, LLC and changed its name to Kindly MD, Inc. in March 2022. The company was incorporated in 2019 and is based in Salt Lake City, Utah.
At a Glance
Live Snapshotnaka
Selling, General and Administrative Expenses
Last Annual Value
22.85M
3-Year CAGR
122%
5-Year CAGR
93%
10-Year CAGR
39%
Nakamoto Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Nakamoto Inc. NASDAQ:NAKA | 22.85M | 156.4% | 93.0% | N/A | |
 Definitive Healthcare Corp. NASDAQ:DH | 133.26M | -4.6% | 8.3% | N/A | |
 Agilon Health, Inc. NYSE:AGL | 238.54M | -5.8% | -11.0% | N/A | |
 Allogene Therapeutics, Inc. NASDAQ:ALLO | 56.78M | -7.5% | -5.2% | N/A | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 36.11M | 42.5% | 42.5% | N/A | |
 LifeMD, Inc. NASDAQ:LFMD | 144.01M | 4.0% | 3.4% | 41.5% | |
 908 Devices Inc. NASDAQ:MASS | 38.53M | N/A | 3.6% | N/A | |
 TruBridge, Inc. NASDAQ:TBRG | 104.20M | -0.0% | 8.1% | 3.7% | |
 Voyager Therapeutics, Inc. NASDAQ:VYGR | 37.54M | 1.6% | 0.2% | 11.0% | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 60.09M | 10.3% | 19.6% | N/A | |
 Lyell Immunopharma, Inc. NASDAQ:LYEL | 45.13M | -12.3% | -12.7% | N/A |
Nakamoto Inc. Fair Value Envelope
Related Guides
Continue your NAKA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.